155例软组织肉瘤的S期分数：与临床结果的相关性

S-phase fraction of 155 soft tissue sarcomas: correlation with clinical outcome.

作者信息

Huuhtanen R L, Blomqvist C P, Wiklund T A, Virolainen M J, Elomaa A I, Pan Y, Tribukait B

机构信息

Department of Oncology, Helsinki University Central Hospital, Finland.

出版信息

Cancer. 1996 May 1;77(9):1815-22. doi: 10.1002/(SICI)1097-0142(19960501)77:9<1815::AID-CNCR9>3.0.CO;2-A.

DOI:10.1002/(SICI)1097-0142(19960501)77:9<1815::AID-CNCR9>3.0.CO;2-A

PMID:8646679

Abstract

BACKGROUND

Traditionally, grade is considered the most important prognostic factor for soft tissue sarcomas (STS). However, because of the alleged difficulties in reproducibility of grading, new, objectively determined prognostic factors would be of value. The aim of our study was to establish if S-phase fraction (SPF) measured with flow cytometry was of prognostic significance for STS.

METHODS

In this study, we included all 193 adult STS patients with superficial trunk or limb tumors who were treated by the Helsinki University Central Hospital (HUCH) STS group between January 1987 and May 1993. One hundred and seventy-two formalin fixed paraffin embedded tumor samples were available. SPF measurement was successful in 155 cases.

RESULTS

Eighty-six cases were diploid. Ploidy was found to have no effect on overall survival. The median SPF was 6.8% (diploid tumors, 4% and nondiploid tumors, 12.9%). A high SPF predicted a shorter survival in patients with diploid tumors (P=0.003). The prognostic value was even stronger when we studied disease specific survival and excluded from analysis samples that contained less than 50% tumor cells (P=0.011). However, no prognostic value could be detected in nondiploid tumors or in the material as a whole.

CONCLUSIONS

Our results suggest that high SPF is an adverse prognostic factor for survival of patients with diploid STS. However, further studies are needed to confirm these results.

摘要

背景

传统上，分级被认为是软组织肉瘤（STS）最重要的预后因素。然而，由于分级的可重复性存在所谓的困难，新的、客观确定的预后因素将具有价值。我们研究的目的是确定通过流式细胞术测量的S期分数（SPF）对STS是否具有预后意义。

方法

在本研究中，我们纳入了1987年1月至1993年5月间由赫尔辛基大学中心医院（HUCH）STS组治疗的所有193例患有浅表躯干或肢体肿瘤的成年STS患者。有172个福尔马林固定石蜡包埋的肿瘤样本可用。SPF测量在155例中成功。

结果

86例为二倍体。发现倍性对总生存期没有影响。SPF中位数为6.8%（二倍体肿瘤为4%，非二倍体肿瘤为12.9%）。高SPF预示二倍体肿瘤患者生存期较短（P = 0.003）。当我们研究疾病特异性生存期并从分析样本中排除肿瘤细胞少于50%的样本时，预后价值更强（P = 0.011）。然而，在非二倍体肿瘤或整个材料中未检测到预后价值。